AR059826A1 - Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble - Google Patents

Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble

Info

Publication number
AR059826A1
AR059826A1 ARP070101011A ARP070101011A AR059826A1 AR 059826 A1 AR059826 A1 AR 059826A1 AR P070101011 A ARP070101011 A AR P070101011A AR P070101011 A ARP070101011 A AR P070101011A AR 059826 A1 AR059826 A1 AR 059826A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
arylalkyl
cycloalkyl
alkoxy
Prior art date
Application number
ARP070101011A
Other languages
English (en)
Original Assignee
Univ California
Arete Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Arete Therapeutics Inc filed Critical Univ California
Publication of AR059826A1 publication Critical patent/AR059826A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase

Abstract

Un compuesto que tiene la formula (1): donde R1 es un miembro seleccionado del grupo formado por alquilo C1-8, arilalquilo C0-8, cicloalquilo C3-12 y heterociclilo, cada uno opcionalmente sustituido con entre 1 y 2 sustituyentes cada uno seleccionado en forma independiente del grupo formado por alquilo C1-8, heteroalquilo C1-8, arilo, heteroarilo; donde dichas porciones cíclicas son monocíclicas o policíclicas; Y1 se selecciona del grupo formado por un enlace, C(R5)2, NR5 y O; Y2 se selecciona del grupo formado por un enlace, NR5 y O; cada R2, R3 y R5 se selecciona independientemente del grupo formado por H, alquilo y COR6; A es heterociclilo, opcionalmente sustituido con entre 1 y 2 sustituyentes R7; L se selecciona del grupo formado por un enlace directo, alquileno C1-12, heteroalquileno C1-12, cicloalquileno C3-6, arileno, heteroarileno, -CO-, -SOm- y -Se-; R4 se selecciona del grupo formado por H, alquilo C1-8, alquenilo C2-6, alquinilo C2-6, heteroalquilo C1-8, arilalquilo C0-8, cicloalquilo C3-12 y heterociclilo, cada uno opcionalmente sustituido con entre 1 y 2 sustituyentes cada uno seleccionado en forma independiente del grupo formado por alquilo C1-8, halo, heteroalquilo C1-8, arilalquilo C0-8, COR6, S(O)mR6 y heteroarilo; cada R6 se selecciona independientemente del grupo formado por H, alquilo C1-8, OH, alcoxi C1-8 y amino; cada R7 se selecciona del grupo formado por halo, nitro, alquilo C1-8, alquilamino C1-8, hidroxialquilo C1-8, haloalquilo C1-8, carboxilo, hidroxilo, alcoxi C1-8, alcoxi C1-8-alcoxi C1-8, haloalcoxi C1-8, tioalquilo C1-8, arilo, ariloxi, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-8, heteroarilo, arilalquilo C1-8, heteroarilalquilo C1-8, alquenilo C2-8 que contiene de 1 a 2 enlaces dobles, alquinilo C2-8 que contiene de 1 a 2 enlaces triples, grupos alqu(en)(in)ilo C4-8, ciano, formilo, alquil C1-8carbonilo, arilcarbonilo, heteroarilcarbonilo, alcoxi C1-8carbonilo, ariloxicarbonilo, aminocarbonilo, alquil C1- 8aminocarbonilo, dialquil C1-8aminocarbonilo, arilaminocarbonilo, diarilaminocarbonilo, arilalquil C1-8aminocarbonilo, haloalcoxi C1-8, alqueniloxi C2-8, alquiniloxi C2-8, arilalcoxi C1-8, aminoalquilo C1-8, alquil C1-8aminoalquilo C1-8, dialquilC1- 8aminoalquilo C1-8, arilaminoalquilo C1-8, amino, dialquil C1-8amino, arilamino, arilalquil C1-8amino, alquil C1-8carbonilamino, arilcarbonilamino, azido, mercapto, alquil C1-8tio, ariltio, haloalquil C1-8tio, tiociano, isotiociano, alquil C1- 8sulfinilo, alquil C1-8sulfonilo, arilsulfinilo, arilsulfonilo, aminosulfonilo, alquil C1-8aminosulfonilo, dialquil C1-8aminosulfonilo y arilaminosulfonilo; el suscripto n es un numero entero de 0 a 1; el suscripto m es un numero entero entre 0 y 2; y sus derivados farmacéuticamente aceptables.
ARP070101011A 2006-03-13 2007-03-12 Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble AR059826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78217206P 2006-03-13 2006-03-13

Publications (1)

Publication Number Publication Date
AR059826A1 true AR059826A1 (es) 2008-04-30

Family

ID=38229180

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101011A AR059826A1 (es) 2006-03-13 2007-03-12 Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble

Country Status (16)

Country Link
US (3) US8188289B2 (es)
EP (1) EP2029539B1 (es)
JP (1) JP5298005B2 (es)
KR (1) KR20080109846A (es)
CN (1) CN101405264B (es)
AR (1) AR059826A1 (es)
AU (1) AU2007225170B2 (es)
BR (1) BRPI0708788A2 (es)
CA (1) CA2646154A1 (es)
EA (1) EA200801969A1 (es)
IL (1) IL193539A0 (es)
MX (1) MX2008011667A (es)
NZ (1) NZ570657A (es)
TW (1) TW200808723A (es)
WO (1) WO2007106525A1 (es)
ZA (1) ZA200807266B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
EP1608319A4 (en) * 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
AU2005295167B2 (en) 2004-10-20 2012-05-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US20090215894A1 (en) * 2005-08-12 2009-08-27 Regents Of The University Of California Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof
US20080076770A1 (en) * 2006-09-25 2008-03-27 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
TW200825072A (en) * 2006-10-20 2008-06-16 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
US20080200444A1 (en) * 2006-10-20 2008-08-21 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
JP2010509236A (ja) * 2006-11-03 2010-03-25 アレテ セラピューティクス， インコーポレイテッド 慢性関節リウマチの処置のための可溶性エポキシドヒドロラーゼ阻害剤
US20080207908A1 (en) * 2007-01-29 2008-08-28 Arete Therapeutics, Inc Processes for the preparation of piperidinyl-substituted urea compounds
CN101594858A (zh) * 2007-01-29 2009-12-02 亚瑞特医疗公司 用于治疗代谢综合症和相关病症的可溶性环氧化物水解酶抑制剂
AU2007349176A1 (en) * 2007-03-13 2008-09-18 Arete Therapeutics, Inc. 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors
WO2008128986A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
US20110098322A1 (en) * 2007-08-06 2011-04-28 The Regents Of The University Of California Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
WO2009035951A2 (en) * 2007-09-11 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
DK2214487T3 (da) 2007-10-11 2014-02-10 Glaxosmithkline Llc Nye sEH-inhibitorer og deres anvendelse
WO2009049154A1 (en) * 2007-10-11 2009-04-16 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
US8008483B2 (en) * 2007-10-11 2011-08-30 GlaxoSmithKline, LLC sEH inhibitors and their use
EP2219450A4 (en) * 2007-11-08 2012-01-25 Univ California RELIEF OF NEUROPATHIC PAIN USING EET AND SEH INHIBITORS
US20100261743A1 (en) * 2007-12-06 2010-10-14 Glaxosmithkline Llc Novel seh inhibitors and their use
US20090247521A1 (en) * 2007-12-28 2009-10-01 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
US20090270452A1 (en) * 2008-04-18 2009-10-29 Arete Therapeutics, Inc. Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
CL2009000925A1 (es) * 2008-04-18 2009-06-19 Arete Therapeutics Inc Compuestos derivados de piperidin ureas y tioureas sustituidas, inhibidores de epoxido hidrolasa soluble; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de hipertension, inflamacion, complicaciones diabeticas, artritis, asma, entre otras.
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
US20100063583A1 (en) * 2008-08-29 2010-03-11 Arete Therapeutics, Inc. Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases
EP2334180A4 (en) * 2008-09-15 2013-07-03 Univ California RESTRICTING DISEASES WITH A COMBINATION OF ACTIVE SUBSTANCES TO INCREASE THE CONCENTRATION OF EPOXYGENATED FATTY ACIDS AND ACTIVE SUBSTANCES TO INCREASE THE CAMP CONCENTRATION
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
TW201041868A (en) * 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
EP2528604B1 (en) * 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
WO2011143607A1 (en) * 2010-05-14 2011-11-17 The Regents Of The University Of California Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
JPWO2013115294A1 (ja) * 2012-01-31 2015-05-11 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
CN104185626A (zh) 2012-03-29 2014-12-03 东丽株式会社 3-哌啶甲酸衍生物和其药物用途
WO2014111465A1 (en) * 2013-01-17 2014-07-24 Sanofi Isomannide derivatives as inhibitors of soluble epoxide hydrolase
WO2014193969A2 (en) * 2013-05-28 2014-12-04 The Regents Of The University Of California Compounds for the treatment of hypertension and hypertensive end stage renal disease
EP2881390A1 (en) 2013-12-04 2015-06-10 Sanofi Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
ES2871027T3 (es) 2014-03-27 2021-10-28 Eicosis Llc Inhibidores potentes de la epóxido hidrolasa soluble
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
MX2018001135A (es) * 2015-07-28 2018-05-23 Univ Barcelona Analogos de adamantilureas como inhibidores de epoxido hidrolasa soluble.
EP3390396B1 (en) 2015-12-15 2022-07-06 Astrazeneca AB Isoindole compounds
US20200317813A1 (en) 2016-05-25 2020-10-08 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Treatment and diagnosis of non-proliferative diabetic retinopathy
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
EP3584236A1 (en) * 2018-06-20 2019-12-25 Universitat de Barcelona Polycyclic compounds soluble epoxide hydrolase inhibitors
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
US20230192626A1 (en) * 2020-05-26 2023-06-22 Baylor College Of Medicine Novel soluble epoxide hydrolase inhibitors and method of use thereof
WO2022076881A1 (en) * 2020-10-09 2022-04-14 The Regents Of The University Of California Methods of treating alzheimer's disease using slow tight binding soluble epoxide hydrolase inhibitors
US11766419B2 (en) 2021-01-08 2023-09-26 Banasthali Vidyapith Mebeverine as soluble epoxide hydrolase inhibitor
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE757606A (fr) * 1969-10-21 1971-04-01 Western Electric Co Systeme de traitement de donnees
US3755415A (en) * 1969-10-28 1973-08-28 Cilag Chem Ag Adamantyl urea derivatives
US3703537A (en) 1969-10-28 1972-11-21 Cilag Chemie Adamantyl urea derivatives
DD123466A1 (es) * 1975-12-01 1976-12-20
US4252954A (en) * 1979-10-25 1981-02-24 Eli Lilly And Company Salts of dihalo-3,4-dihydro-3-oxo-2-quinoxaline carboxylic acids and hindered amines
JPS58118567A (ja) * 1982-01-07 1983-07-14 Mitsui Toatsu Chem Inc スルファモイル安息香酸誘導体
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
JPH0413666A (ja) * 1990-05-08 1992-01-17 Yamanouchi Pharmaceut Co Ltd １―（アルコキシフェニル）―３―（４，５，６，７―テトラヒドロベンズイミダゾリル）ウレア
US5189036A (en) * 1990-06-20 1993-02-23 Schering Ag Imidazolylbenzoyl substituted heterocycles
JPH05294935A (ja) 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
US5445956A (en) 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
JPH07133224A (ja) * 1993-11-10 1995-05-23 Kyowa Hakko Kogyo Co Ltd 動脈硬化治療薬
US5637113A (en) * 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
JP3583489B2 (ja) * 1994-12-22 2004-11-04 日清紡績株式会社 カルボジイミド誘導体
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
WO1997019682A1 (en) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
FR2750991A1 (fr) * 1996-07-12 1998-01-16 Pf Medicament Nouveaux benzodioxannes et 1-(2h)-benzopyrannes, leur preparation et leur utilisation comme medicament
ES2186907T3 (es) * 1996-07-23 2003-05-16 Neurogen Corp Ciertos derivados de bencilamina sustituidos; una nueva clase de ligandos especificos del neuropeptido y1.
US6693130B2 (en) * 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US6531506B1 (en) * 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6391891B1 (en) * 1997-08-09 2002-05-21 Smithkline Beecham Plc Bicyclic compounds as ligands for 5-HT1 receptors
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
AU771367B2 (en) 1998-08-20 2004-03-18 Cook Medical Technologies Llc Coated implantable medical device
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6351506B1 (en) 1999-04-19 2002-02-26 National Semiconductor Corporation Switched capacitor filter circuit having reduced offsets and providing offset compensation when used in a closed feedback loop
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
CO5190710A1 (es) 1999-06-15 2002-08-29 Smithkline Beecham Corp Antagonistas de un receptor de il-8 un receptor de il-8
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
JP4548884B2 (ja) * 1999-12-03 2010-09-22 興和創薬株式会社 ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン誘導体
WO2001042212A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US6290722B1 (en) * 2000-03-13 2001-09-18 Endovascular Technologies, Inc. Tacky attachment method of covered materials on stents
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
DE10051321A1 (de) * 2000-10-17 2002-04-25 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
MXPA04000707A (es) 2001-07-26 2004-04-20 Schering Corp Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
AU2002327534A1 (en) * 2001-08-17 2003-03-03 Merck And Co., Inc. Tyrosine kinase inhibitors
JPWO2003062234A1 (ja) * 2002-01-23 2005-05-19 山之内製薬株式会社 キノキサリン化合物
US20030139469A1 (en) 2002-01-23 2003-07-24 The Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
GB0203994D0 (en) * 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
WO2003076426A2 (en) * 2002-03-04 2003-09-18 Pharmacia & Upjohn Company Pyridinyloxy derivatives as 5-ht receptor ligands
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
AU2003241453A1 (en) * 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
GB0211759D0 (en) 2002-05-22 2002-07-03 Glaxo Group Ltd Novel compounds
AU2003251828A1 (en) * 2002-07-12 2004-02-02 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
GB0218326D0 (en) * 2002-08-07 2002-09-11 Glaxo Group Ltd Compounds
WO2004024710A1 (en) * 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US20060094716A1 (en) 2002-09-17 2006-05-04 Actelion Pharmaceuticals Ltd 1-Pyridin-4-yl-urea derivatives
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
JP4613157B2 (ja) * 2003-01-14 2011-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
EP1608319A4 (en) 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
GB0308801D0 (en) 2003-04-16 2003-05-21 Celltech R&D Ltd Chemical compounds
WO2004111031A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
DK1658269T3 (da) * 2003-06-12 2009-01-12 Abbott Lab Kondenserede forbindelser som inhiberer vanilloidreceptorsubtype 1 (VR1)-receptoren
CA2534905A1 (en) 2003-08-08 2005-02-17 Janssen Pharmaceutica, N.V. Pyridyl piperazinyl ureas
WO2005030209A1 (en) * 2003-09-26 2005-04-07 Actelion Pharmaceuticals Ltd Pyridine derivatives and use thereof as urotensin ii antagonists
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
KR20070006698A (ko) * 2003-12-23 2007-01-11 액티브 바이오틱스 인코포레이티드 리파마이신 유사체 및 그의 용도
JP2007529496A (ja) 2004-03-19 2007-10-25 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体
MXPA06013022A (es) 2004-05-12 2007-01-23 Squibb Bristol Myers Co Antagonistas de urea de receptor p2y1 utiles en el tratamiento de condiciones tromboticas.
DK1761520T3 (da) * 2004-06-23 2008-10-27 Lilly Co Eli Kinaseinhibitorer
US7560462B2 (en) * 2004-07-02 2009-07-14 Icos Corporation Compounds useful for inhibiting CHK1
FR2872813B1 (fr) * 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
AU2005295167B2 (en) 2004-10-20 2012-05-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase

Also Published As

Publication number Publication date
US8188289B2 (en) 2012-05-29
US20130137726A1 (en) 2013-05-30
US20130274476A1 (en) 2013-10-17
CN101405264A (zh) 2009-04-08
WO2007106525A1 (en) 2007-09-20
IL193539A0 (en) 2009-02-11
EP2029539A1 (en) 2009-03-04
EP2029539B1 (en) 2016-06-29
EA200801969A1 (ru) 2008-12-30
JP5298005B2 (ja) 2013-09-25
MX2008011667A (es) 2009-02-12
CN101405264B (zh) 2013-07-24
AU2007225170B2 (en) 2012-11-01
ZA200807266B (en) 2009-11-25
JP2009530287A (ja) 2009-08-27
BRPI0708788A2 (pt) 2011-06-14
US8501783B2 (en) 2013-08-06
TW200808723A (en) 2008-02-16
CA2646154A1 (en) 2007-09-20
US20070225283A1 (en) 2007-09-27
KR20080109846A (ko) 2008-12-17
US9029550B2 (en) 2015-05-12
AU2007225170A1 (en) 2007-09-20
NZ570657A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
AR059826A1 (es) Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
AR048055A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
CO6321274A2 (es) Compuestos de pirazol acetamida n-sustituida como activadores de glucoquinasa
PE20070343A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
AR061847A1 (es) Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas.
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR075510A1 (es) Inhibidores del virus de la hepatitis c
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
PE20080855A1 (es) Derivados de pirazina-2-carboxamida
PE20120509A1 (es) Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR088218A1 (es) Compuestos heterociclicos utiles como inhibidores de pi3k
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
PE20150041A1 (es) Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
AR083199A1 (es) Compuestos de n-heteroarilo con unidad de puente ciclico
AR071452A1 (es) Inhibidores de hsp90
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
AR066169A1 (es) Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
AR074670A1 (es) Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
CO6440511A2 (es) Compuesto que contienen nitrogeno y composicion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure